Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem wolno rozwijającego się chłoniaka B-komórkowego (follicular lymphoma stopnia 1-2 lub 3A, lub marginal zone lymphoma)
- •Choroba w stadium Ann Arbor II-IV
- •Nigdy wcześniej nie leczone chłoniakiem
- •Niska objętość guza (małe rozmiary zmian nowotworowych)
- •Co najmniej jeden mierny ognisk zmian (widoczny w badaniach obrazowych)
- •Sprawność fizyczna pozwalająca na leczenie (ECOG 0-2)
- •Prawidłowe wyniki badań nerek i wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Ajay Gopal
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.